Transaldolase deficiency causes a starvation-like response that decreases animal fat content and rewires lipid metabolism gene expression. by Christopher F. Bennett (3875731)

“…<p><b>(A)</b> Intestinal fat staining decreases from RNAi knockdown of <i>tald-1</i> or <i>cco-1</i>. …”

The primer information. by Guangxiao Ni (19713106)

Subjects:

Evans Blue extravasation between groups. by Guangxiao Ni (19713106)

Subjects:

Fibrosis markers. by Dwight D. Harris (14484648)

Immunoblotting for TGF-beta, alpha-actinin, MMP-13, and mTOR. by Dwight D. Harris (14484648)

Immunoblotting for JAK, STAT, and SMAD. by Dwight D. Harris (14484648)

Decreased Na_v1.5 expression in <i>Scn5a</i>^+/− mice. by Anne-Laure Leoni (366926)

TUDCA decreases MPO with improved mitochondrial biogenesis, mitochondria-ER contact, and alveolar formation of HOX neonatal rat lungs. by Kirkwood A. Pritchard Jr. (13449794)

“…<p>(<b>A</b>) The increased MPO levels in HOX neonatal lungs are decreased by TUDCA treatment (0.1±0.1-fold; n = 6, p<0.05). …”

Immunoblotting FOXO1 and insulin receptors. by Dwight D. Harris (14484648)

Immunoblotting for insulin sensitivity markers. by Dwight D. Harris (14484648)

The 5-point summary of CPM dataset. by Gaurav Sandeep Dave (21519884)

Activation of mGluR5 site-specifically decreases spine density in the nucleus accumbens. by Kellie S. Gross (3115299)

Average giving in the 5€, 100€, and 1000€ treatments. by Pablo Brañas-Garza (336425)

Overexpression of miR132 decreases synaptic depression in response to a train of stimuli, but does not affect the rate of refilling of the RRP. by Talley J. Lambert (358201)

Loss of Rumi leads to intracellular accumulation and decreased IRS levels of Eys in a temperature dependent manner at the mid-pupal stage. by Amanda R. Haltom (664189)

“…The scale bar in A applies to A–G′ and is 5 µm. (A,A′) A wild-type ommatidium at 55% PD raised at 18°C. …”

RGS5 deletion resulted in decreased peripheral insulin sensitivity and suppressed the Akt/GSK3β signaling pathway in mice fed an HF for 24 weeks. by Wei Deng (17330)

Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”

How the variation in inhibitor concentration throughout one day affects the value of IC₅₀/(IC₅₀ + [R]) for different Abl1 inhibitors. by J. Roadnight Sheehan (20141887)

Supplementary Material for: Platelet Decreases following Continuous Renal Replacement Therapy Initiation as a Novel Risk Factor for Renal Nonrecovery by Griffin B.R. (8570007)

Validation accuracy of our custom CNN model with the directional filters over 5 folds. by Salih Furkan Atici (12988243)